Endoscopic radiofrequency ablation for malignant biliary obstruction

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F21%3A00081768" target="_blank" >RIV/00023001:_____/21:00081768 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/21:N0000097

Výsledek na webu

<a href="https://www.wjgnet.com/1948-5204/full/v13/i10/1383.htm" target="_blank" >https://www.wjgnet.com/1948-5204/full/v13/i10/1383.htm</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4251/wjgo.v13.i10.1383" target="_blank" >10.4251/wjgo.v13.i10.1383</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Endoscopic radiofrequency ablation for malignant biliary obstruction

Popis výsledku v původním jazyce

Cholangiocarcinoma and pancreatic cancer are the most common causes of malignant biliary obstruction. The majority of patients are diagnosed at a late stage when surgical resection is rarely possible. In these cases, palliative chemotherapy and radiotherapy provide only limited benefit and are associated with poor survival. Radiofrequency ablation (RFA) is a procedure for locoregional control of tumours, whereby a high-frequency alternating current turned into thermal energy causes coagulative necrosis of the tissue surrounding the catheter. The subsequent release of debris and tumour antigens by necrotic cells can stimulate local and systemic immunity. The development of endoluminal RFA catheters has led to the emergence of endoscopically delivered RFA, a treatment mainly used for malignant biliary strictures to prolong survival and/or stent patency. Other indications include recanalisation of occluded biliary stents and treatment of intraductal ampullary adenoma or benign biliary strictures. This article presents a comprehensive review of endobiliary RFA, mainly focusing on its use in patients with malignant biliary obstruction. The available data suggest that biliary RFA may be a promising modality, having positive impacts on survival and stent patency and boasting a reasonable safety profile. However, further studies with better characterised and stratified patient populations are needed before the method becomes accepted within routine clinical practice. © 2021. The Author(s). Published by Baishideng Publishing Group Inc. All Rights Reserved.

Název v anglickém jazyce

Endoscopic radiofrequency ablation for malignant biliary obstruction

Popis výsledku anglicky

Cholangiocarcinoma and pancreatic cancer are the most common causes of malignant biliary obstruction. The majority of patients are diagnosed at a late stage when surgical resection is rarely possible. In these cases, palliative chemotherapy and radiotherapy provide only limited benefit and are associated with poor survival. Radiofrequency ablation (RFA) is a procedure for locoregional control of tumours, whereby a high-frequency alternating current turned into thermal energy causes coagulative necrosis of the tissue surrounding the catheter. The subsequent release of debris and tumour antigens by necrotic cells can stimulate local and systemic immunity. The development of endoluminal RFA catheters has led to the emergence of endoscopically delivered RFA, a treatment mainly used for malignant biliary strictures to prolong survival and/or stent patency. Other indications include recanalisation of occluded biliary stents and treatment of intraductal ampullary adenoma or benign biliary strictures. This article presents a comprehensive review of endobiliary RFA, mainly focusing on its use in patients with malignant biliary obstruction. The available data suggest that biliary RFA may be a promising modality, having positive impacts on survival and stent patency and boasting a reasonable safety profile. However, further studies with better characterised and stratified patient populations are needed before the method becomes accepted within routine clinical practice. © 2021. The Author(s). Published by Baishideng Publishing Group Inc. All Rights Reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

<a href="/cs/project/NV17-30281A" target="_blank" >NV17-30281A: Radiofrekvenční ablace v terapii onemocnění žlučových cest a pankreatu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

World journal of gastrointestinal oncology

ISSN

1948-5204

e-ISSN

—

Svazek periodika

13

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

14

Strana od-do

1383-1396

Kód UT WoS článku

000721601200010

EID výsledku v databázi Scopus

2-s2.0-85117889515